TCRR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 mai 2023 @ 22:00):

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer...

Stats
Dagens volum	3.75M
Gjennomsnittsvolum	325 040
Markedsverdi	58.11M
EPS	$0 ( 2024-03-21 )
Neste inntjeningsdato	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.352
ATR14	$0.105 (7.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-01	Tang Kevin C	Sell	4 394 800	Common Stock
2023-06-01	Ubs Oncology Impact Fund L.p.	Sell	3 370 982	Common Stock
2023-06-01	Mpm Sunstates Fund, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Mpm Bioventures 2014, L.p.	Sell	4 158 964	Common Stock
2023-06-01	Gadicke Ansbert	Sell	3 370 982	Common Stock

INSIDER POWER
-89.65
Last 99 transactions
Buy: 1 629 400 \| Sell: 23 030 678

Volum Korrelasjon

Lang: 0.06 (neutral)

Kort: -0.70 (moderate negative)

Signal:(27.338) Neutral

TCR2 Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
ROAD	0.928
STLD	0.926
RAIL	0.918
HEES	0.911
EQRR	0.906
FTXN	0.903
DXPE	0.9
PIE	0.896
THRN	0.895
ATOS	0.895

10 Mest negative korrelasjoner
BOCH	-0.936
BNIXU	-0.929
RGC	-0.919
ISPC	-0.897
MMAC	-0.891
ACXP	-0.885
HCDIP	-0.883
TSP	-0.876
NETE	-0.87
ORPH	-0.867

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

TCR2 Therapeutics Inc Korrelasjon - Valuta/Råvare

0.32
( neutral )

0.73
( moderate )

0.00
( neutral )

0.25
( neutral )

-0.59
( weak negative )

-0.77
( moderate negative )

TCR2 Therapeutics Inc Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-3.93

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-3.93

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-3.57

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.40

Financial Reports:

No articles found.

TCR2 Therapeutics Inc

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sanntidsoppdatering for TCR2 Therapeutics Inc [TCRR]

Upcoming Earnings Alert